Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gefitinib in Resectable Esophageal Cancer
NCT00258297Phase 2Terminated
- Sponsor
- University of Rochester
- Start
- Apr 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in esophageal cancer, sponsored by University of Rochester. Primary endpoints: Safety and tolerability of neoadjuvant gefitinib up to 6 months and Effect on the signaling pathways by immunohistochemistry. Started Apr 2004; status: terminated.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00258297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258297.